Trial Profile
Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab PCA System (Zalviso) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Sufentanil (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors AcelRx Pharmaceuticals; Talphera
- 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
- 28 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.